Overview

Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Certoparin
Dihydroergotamine
Heparin, Low-Molecular-Weight